Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5336006 | 0.93 | ESR2 (0.54) | ESR2ESR1 | |
| SCHEMBL5336079 | 0.93 | ESR2 (0.54) | ESR2ESR1 | |
| SCHEMBL5340411 | 0.91 | ESR2 (0.55) | ESR2ESR1 | |
| SCHEMBL5336152 | 0.89 | ESR1 (0.53) | ESR2ESR1 | |
| SCHEMBL2413921 | 0.88 | ESR2 (0.60) | ESR2ESR1 | |
| SCHEMBL5340048 | 0.88 | ESR2 (0.54) | ESR2ESR1 | |
| SCHEMBL5338869 | 0.87 | ESR2 (0.56) | ESR2ESR1 | |
| SCHEMBL5336090 | 0.85 | ESR2 (0.58) | ESR2ESR1 | |
| SCHEMBL2419519 | 0.84 | ESR2 (0.60) | ESR2ESR1 | |
| SCHEMBL5728523 | 0.84 | ESR2 (0.54) | ESR2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157604-B2 | Selective estrogen receptor modulators | MERCK & CO., INC. (US) | 2007-01-02 | — | — | US | claimed |
| EP-1418900-A4 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2006-01-25 | — | — | EP | claimed |
| US-20040210080-A1 | Selective estrogen receptor modulators | MERCK & CO., INC. | 2004-10-21 | — | — | US | claimed |
| EP-1418900-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2004-05-19 | — | — | EP | claimed |
| WO-2003015761-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-02-27 | — | — | WO | claimed |
| US-20070213334-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CARPINO PHILIP A | 2007-09-13 | — | — | US | disclosed |
| US-7241788-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-7232823-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-7230024-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC (US) | 2007-06-12 | — | — | US | disclosed |
| US-7157604-B2 | Selective estrogen receptor modulators | MERCK & CO., INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157604-B2 | Selective estrogen receptor modulators | MERCK & CO., INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157604-B2 | Selective estrogen receptor modulators | MERCK & CO., INC. (US) | 2007-01-02 | — | — | US | disclosed |
| WO-2005009974-A1 | IMIDAZOLE COMPOUNDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| WO-2004108728-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2004-12-16 | — | — | WO | disclosed |
| US-20040248881-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-12-09 | — | — | US | disclosed |
| WO-2004094429-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040214855-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-10-28 | — | — | US | disclosed |
| US-20040210080-A1 | Selective estrogen receptor modulators | MERCK & CO., INC. | 2004-10-21 | — | — | US | disclosed |
| EP-1418900-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003015761-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248881-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | ESR2 328/4885ESR1 807/4885 |
| US-20070213334-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR2, CNR1, GPR18 | ESR2 342/4885ESR1 853/4885 |
| US-20040210080-A1 | Selective estrogen receptor modulators | GPER1, ESR2, ESR1 | ESR2 2/4885ESR1 3/4885 |
| US-20040214855-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | ESR2 333/4885ESR1 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.